The efficacy of drug ‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancer

BackgroundDrug ‐eluting beads bronchial arterial chemoembolization (DEB‐BACE) can embolize the tumor‐feeding artery and also be loaded with antitumor drugs, which can be released slowly into the local tumor environment. The effect of DEB‐BACE in patients with lung cancer remains unclear. We evaluated the e fficacy and safety of DEB‐BACE with gemcitabine‐loaded CalliSpheres beads in patients with non‐small cell lung cancer (NSCLC).MethodsFrom May 2017 to December 2018, six patients with NSCLC who were ineligible or refused to receive standard treatment underwent DEB ‐BACE with gemcitabine‐loaded CalliSpheres beads. The primary endpoint was the objective response rate (ORR). The secondary endpoints were progression‐free survival (PFS), overall survival (OS), and quality of life. Safety was evaluated by the occurrences of adverse events and serious adverse events.ResultsAll patients were treated with DEB ‐BACE loaded with gemcitabine (800 mg) using CalliSpheres beads. Five patients also received transarterial infusion with nedaplatin (80–100 mg). Of the six patients, five underwent a second session of DEB‐BACE, with intervals of one month between the first and second session. The median follow‐up time was 16.5 months (7.0–23.0 months). ORR and disease control rate were 50.0% and 100.0%, 50.0% and 83.3%, 50.0% and 66.7% respectively at 2, 4, and 6 months after DEB‐BACE. One patient maintained a partial response and the ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Authors: Herth FJF, Reinmuth N, Wormanns D, Antoch G, Biederer J, Vogel-Claussen J, Kauczor HU, Pfeifer M, Vorstand der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, Vorstand der Deutschen Röntgengesellschaft Abstract Substantial new data on early detection of lung cancer with low-dose CT has become available since the last joint statement of the German Roentgenological Society and the German Respiratory Society was published in 2011. The German S3 guideline on lung cancer was revised in 2018 and now contains a weak recommendation towards early detection of lung cancer with low-dose CT in a...
Source: Pneumologie - Category: Respiratory Medicine Tags: Pneumologie Source Type: research
Publication date: 21–27 September 2019Source: The Lancet, Volume 394, Issue 10203Author(s): The Lancet
Source: The Lancet - Category: General Medicine Source Type: research
ConclusionsAdiponectin had no role in the development of gastropathy. Patients with gastropathy had a significant increase in the serum level of cholesterol and triglyceride. There is a significant negative correlation between adiponectin and weight, body mass index, waist circumference, triglyceride, and low-density lipoprotein.
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
Conclusions: The AS04-adjuvanted HPV-16/18 vaccine administered according to a 2-dose schedule to girls 4–6 years of age induced a high and sustained immunologic response with an acceptable safety profile during the 30 months following vaccination.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. In 2004, Dr. Marc Garnick, Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org, reported that in some men, an ADT drug called aberelix lengthens the time it tak...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Living With Prostate Cancer Men's Health Prostate Health Prostate Knowledge Treatments HPK Source Type: blogs
Those most likely to skip appointments are men under 30 or over 85, people living in poor areas, and those with gastrointestinal symptoms, the study found.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Publication date: Available online 19 September 2019Source: Seminars in Cancer BiologyAuthor(s): Annie Wai Yeeng Chai, Kue Peng Lim, Sok Ching CheongAbstractOral squamous cell carcinomas (OSCC) are a heterogeneous group of cancers arising from the mucosal lining of the oral cavity. A majority of these cancers are associated with lifestyle risk habits including smoking, excessive alcohol consumption and betel quid chewing. Cetuximab, targeting the epidermal growth factor receptor was approved for the treatment of OSCC in 2006, and remains the only molecular targeted therapy available for OSCC. Here, we reviewed the current ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
We report results of preclinical studies and clinical trials, and discuss the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia. In the future, the numerous experimental studies currently underway will allow us to define the role of SINEs and will possibly permit these substances to be introduced into daily clinical practice.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
BackgroundDrug ‐eluting beads bronchial arterial chemoembolization (DEB‐BACE) can embolize the tumor‐feeding artery and also be loaded with antitumor drugs, which can be released slowly into the local tumor environment. The effect of DEB‐BACE in patients with lung cancer remains unclear. We evaluated the e fficacy and safety of DEB‐BACE with gemcitabine‐loaded CalliSpheres® beads in patients with non‐small cell lung cancer (NSCLC).MethodsFrom May 2017 to December 2018, six patients with NSCLC who were ineligible or refused to receive standard treatment underwent DEB ‐BACE with gemcitabine‐loaded Calli...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Mark E. Gray1,2*, James Meehan2,3, Paul Sullivan4, Jamie R. K. Marland4, Stephen N. Greenhalgh1, Rachael Gregson1, Richard Eddie Clutton1, Carol Ward2, Chris Cousens5, David J. Griffiths5, Alan Murray4 and David Argyle1 1The Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom 2Cancer Research UK Edinburgh Centre and Division of Pathology Laboratories, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom 3School of Engineering and Physical Sciences, Institute of Sensors, Signals and Systems, Heriot-Watt Univer...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Bronchial Tumour | Cancer | Cancer & Oncology | Cough | Environmental Health | Lung Cancer | Non-Small Cell Lung Cancer